Acambis extends Sanofi Pasteur licensing agreement on single-dose JE vaccine to India and Indian subcontinent
Acambis plc announced that it has extended its ChimeriVax(tm)-JE vaccine licensing agreement with sanofi pasteur, the vaccines division of the sanofi-aventis Group, to include India and the Indian subcontinent.
Acambis announced in February 2007 that it had granted sanofi pasteur marketing, distribution and certain manufacturing rights to Acambis' single-dose ChimeriVax(tm)-JE vaccine against Japanese encephalitis (JE). This agreement excluded the US, India and the Indian subcontinent. Acambis had an existing agreement with Bharat Biotech International Limited (Bharat Biotech) for India and Indian subcontinent, which Acambis and Bharat Biotech have mutually agreed to terminate. Acambis has granted rights over those territories to sanofi pasteur.
Acambis will receive from sanofi pasteur an upfront payment, a milestone payment on licensure of the vaccine in India and royalties on sales in these territories. Bharat Biotech has made a significant contribution towards the development of ChimeriVax(tm)-JE and Acambis has agreed to compensate Bharat Biotech. The net financial effect is positive for Acambis.
As with the existing agreement, Acambis will supply bulk ChimeriVax(tm)-JE vaccine to sanofi pasteur from its Canton, MA facility.
Other news from the department business & finance
